Global
Austria
Japan
Belgium
Brazil
Netherlands
Portugal
Czech Republic
Spain
Denmark
Sweden
France
Germany
Taiwan
Ireland
United Kingdom
Italy
We presented new 12-month efficacy and safety data with patisiran from the APOLLO Global Open Label Extension (OLE) Study at the 2018 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, held October 10-13, 2018 in Washington, DC. Gonzalez-Duarte et al. - "Long-Term Use of Patisiran,...
We presented new research on the diagnostic patterns, clinical experience and healthcare utilization of patients with acute hepatic porphyrias at the American College of Gastroenterology 2018 Annual Scientific Meeting, held October 5-10, 2018 in Phildelphia, PA. Ko et al. - "Real-World Analysis of Symptoms, Diagnostic Patterns, and...
We presented further progress on our platform efforts in extrahepatic delivery of novel siRNA conjugates, including CNS and ocular delivery in rat and non-human primates, at the Oligonucleotide Therapeutics Society (OTS) 2018 Annual Meeting, held September 30 to October 3 in Seattle, WA. Read our press...
Data from exploratory cardiac assessments and post-hoc analyses of safety data in the APOLLO Phase 3 study of patisiran, an RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, were published in the journal Circulation. Read the paper in Circulation...